Linkage analysis of Utah pedigrees with heritable hypoalphalipoproteinemia and a family history of early coronary heart disease identified a susceptibility locus on chromosome 11q23 where zinc finger protein 202 (ZNF202) is localized (5, 6) . ZNF202 binds a promoter element found in vascular endothelial growth factor (VEGF ) (7) involved in blood vessel maintenance (8) and also controls promoter elements found in several genes involved in lipid metabolism (7, 9, 10) . This suggests that ZNF202 might be important for the development of atherosclerosis and IHD.
In a previous study (11, 12) , we resequenced the promoter and coding region of ZNF202 in 190 individuals and identified 17 genetic variants, 10 of which were classified as single nucleotide polymorphisms (SNPs) (minor allele frequency Ͼ1%; the 10th SNP, p.V244V, was not typed). In the present study, we tested the following hypotheses: 1) SNPs in ZNF202 predict risk of severe atherosclerosis as determined by ankle brachial index (ABI) in a large crosssectional study of the Danish general population; 2) SNPs in ZNF202 predict risk of IHD in a large prospective study of the Danish general population, and this finding was replicated in 2 independent case-control studies; and 3) ZNF202 g.Ϫ660AϾG is a functional promoter SNP in vitro. (11) , were genotyped in 8,942 individuals in the present and a previous study (11) . The g.Ϫ660AϾG SNP was genotyped in an additional 1,489 individuals (n ϭ 10,431). Information on risk factors was available on all individuals genotyped.
Methods

Subjects. GENERAL POPULATION SAMPLE. The CCHS (Copenhagen City
Ankle brachial index (ABI), a blood pressure reduction in the legs that predicts severe atherosclerosis (15) (16) (17) (18) , was determined only in the approximately 6,000 participants in the 2001 to 2003 examination of the CCHS. Of these, 4,142 participants were genotyped for all 9 SNPs, and an additional 1,213 participants (n ϭ 5,355) were genotyped for g.Ϫ660AϾG. A standard brachial systolic and diastolic blood pressure was recorded on both arms, and systolic ankle blood pressure of the posterior tibial artery on both legs was obtained by Doppler (Huntleigh Mini Dopplex Doppler D900, Huntleigh, United Kingdom). The ABI was the lowest ankle systolic blood pressure divided by the highest brachial systolic blood pressure (15) .
Information on diagnoses of IHD (World Health Organization International Classification of Diseases-8th edition, codes 410 to 414; -10th edition, codes I20 to I25) was collected and verified until the end of 2003 by reviewing all hospital admissions and diagnoses entered in the national Danish Patient Registry, all causes of death entered in the national Danish Causes of Death Registry, and medical records from hospitals and general practitioners. Ischemic heart disease was a previous myocardial infarction (MI) or characteristic symptoms of angina pectoris (non-MI IHD) based on location, character, and duration of pain, and the relation of pain to exercise (19) . A diagnosis of MI required the presence of at least 2 of the following criteria: characteristic chest pain, elevated cardiac enzymes, and electrocardiographic changes indicative of an MI. The MI end points gathered from the national Danish Patient Registry and the national Causes of Death Registry were confirmed independently via medical records of general practitioners and hospitals. Angina pectoris was not confirmed independently, and therefore, some misclassification for angina and thus for the entire IHD group in the prospective study may be present.
PATIENTS WITH IHD-GROUP 1. A second cohort comprised 942 patients from the greater Copenhagen area referred for coronary angiography to Copenhagen University Hospital, during the period from 1991 through 1994. These patients were evaluated by experienced cardiologists and had documented IHD based on characteristic symptoms of angina pectoris (19) , plus at least 1 of the following: stenosis/ atherosclerosis on coronary angiography, a previous MI, or a positive exercise electrocardiography test. The diagnosis of MI was established with the same criteria as in the general population sample.
PATIENTS WITH IHD-GROUP 2.
A third cohort comprised an additional 1,549 patients with IHD referred to coronary angiography at the same hospital during the period 2000 to 2004. The diagnosis of IHD was established by experienced cardiologists using the same criteria as previously mentioned.
Patients with IHD were genotyped for the 9 ZNF202 SNPs mentioned previously. Ankle-brachial index was not available in either of these patient groups. 
CASE-CONTROL STUDIES OF RISK OF ISCHEMIC HEART
DISEASE. Case-control study 1 included 942 cases with IHD and, respectively, 8,998 (g.Ϫ660AϾG only) and 7,644 (8 SNPs) unmatched controls from the CCHS without IHD. Case-control study 2 included 1,549 cases with IHD and the same controls as previously mentioned. Because ABI was not available in either of these patient groups, risk of severe atherosclerosis could not be determined in these 2 studies. Laboratory analyses. SNP GENOTYPING. The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems Inc., Foster City, California) was used to genotype 9 ZNF202 SNPs identified by resequencing ZNF202 as previously described (a 10th SNP, p.V244V, was not typed) (Online Table 1 ) (11) . All genotypes were in HardyWeinberg equilibrium (chi-square: p Ͼ 0.05).
BIOCHEMICAL ANALYSES. Colorimetric and turbidimetric assays were used to measure plasma levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins B and AI (all Boehringer Mannheim GmbH, Mannheim, Germany).
OTHER COVARIATES. The risk factors-diabetes mellitus, smoking, and hypertension-were dichotomized and defined as ever-diabetics (self-reported disease, use of insulin, use of oral hypoglycemic drugs and/or nonfasting plasma glucose Ͼ11.0 mmol/l), ever-smokers (ex-smoker or current smoker), ever-hypertensives (systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg and/or use of antihypertensive drugs). Body mass index was weight (kilograms) divided by height squared (square meters) and was tertilized.
ZNF202 G.؊660G>A EXPRESSION ANALYSIS. Reporter gene constructs for the ZNF202 promoter sequence (Ϫ710 to ϩ124) were cloned into the HindIII and XhoI restriction sites of the pGL3-basic vector (Promega, Mannheim, Germany) and confirmed by sequence analysis. Mutagenesis was conducted using QuikChangeII Site-Directed Mutagenesis Kit (Stratagene, Amsterdam, the Netherlands) to incorporate the ZNF202 g.Ϫ660G SNP. Subsequently, the promoter insert with g.Ϫ660G was subcloned into a new pGL3-basic vector and confirmed by sequence analysis. HepG2 cells were maintained in culture in Dulbecco's Modified Eagle Medium (Gibco, Grand Island, New York) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco) under 5% CO 2 and at 37°C. The day before transfection, cells were seeded in 24-well plates at 1.8 ϫ 10 5 cells per well. HepG2 cells were transiently transfected using FuGENE transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's protocol. To account for variable transfection efficiency, 0.5 g of each ZNF202 promoter construct was cotransfected with 0.1 g of RpL null vector (Promega). After 24 h of incubation, cells were harvested using Passive Lysis Buffer (Promega). The luciferase assay was performed using the dual-luciferase reporter assay system (Promega). Luciferase activity was measured using a TR717 microplate luminometer (Applied Biosystems, Bedford, Massachusetts). Three independent experiments were performed in triplicate with 2 different preparations of DNA. Results were expressed as relative luciferase activity. Statistical analyses. We used the statistical software package Stata (Stata Corp., College Station, Texas). Two-sided probability values Ͻ0.05 were considered significant. In addition, p values were corrected for multiple comparisons for 9 SNPs using the Bonferroni adjustment method, which changed the required significance level from Յ0.05 to Յ0.006 (0.05/9 ϭ 0.006). This correction is for the multiple SNP tests; however, it does not account for the multiple phenotypes and genetic models examined. Noncarriers, heterozygotes, and homozygotes were compared by Kruskal-Wallis analysis of variance for continuous variables and by Pearson chisquare test for categorical variables. In cross-sectional and case-control studies, logistic regression analysis adjusted for age in 10-year age groups was used to estimate odds ratios for severe atherosclerosis (ABI Ͼ0.7 vs. Յ0.7, ABI Ͼ0.9 vs. Յ0.7, ABI Ͼ0.9 vs. Յ0.5), IHD, MI, and angina pectoris as a function of genotypes. In the prospective study, with the use of left truncation (or
Stene et al. July 29, 2008:369-77 Promoter SNP in ZNF202 and Ischemic Heart Disease delayed entry), Cox proportional hazards regression models with age as time scale estimated hazard ratios for IHD, MI, and angina pectoris. For all studies, crosssectional, prospective, and case-control studies, for all end points, and for all 9 SNPs, the following a priori models of inheritance were assumed: an assumption-free model with the most common genotype as the reference group, as well as additive, recessive, and dominant models. Pairwise linkage disequilibrium between the 9 ZNF202 SNPs was estimated in participants in the CCHS using Haploview and expressed as D= and r 2 (20, 21) . Mean relative luciferase activity as a function of Disequilibrium statistics reported as D=, ranging from Ϫ1 to ϩ1, below the black diagonal, and r
2
, ranging from 0 to 1, above the black diagonal. For D=, plus indicates that the rare alleles at each locus segregate together; minus indicates that the rare allele at 1 locus segregates with the common allele at the other locus. g.Ϫ685GϾAϭrs10726530; g.Ϫ660AϾGϭrs10893081; g.-118GϾT not reported; g.ϩ34GϾAϭrs2272142; c.IVS4 -240AϾTϭrs2282641; c.IVS4 -223TϾCϭrs2282642; p.A154V(c.461CϾT)ϭrs1144507; p.K259E(c.775AϾG) not reported, c.*2TϾGϭrs3183878. CCHS ϭ Copenhagen City Heart Study; IVS ϭ intervening sequence; rs ϭ reference single nucleotide polymorphism; SNP ϭ single nucleotide polymorphism. 
Genotype and
ZNF202 g.Ϫ660AϾG genotype was compared by Mann-Whitney U test.
Results
Genotype and minor allele frequencies for all 9 ZNF202 SNPs in the Danish general population are shown in Table 1 . This section of this report focuses on the g.Ϫ660AϾG SNP, while the full tables for all 9 SNPs for all models tested are shown as Online Tables 2 to 11 . Linkage disequilibrium. For the present study, complete genotypes for all 9 SNPs (p.V244V not typed) were available in 8,942 individuals from the general population. The minor alleles of g.Ϫ660AϾG, c.IVS4 -223TϾC, and p.A154V were in linkage disequilibrium (D= ϭ ϩ0.99) and also highly correlated (r 2 ϭ 0.98 to 0.99), indicating that they were on the same haplotype, and that 1 SNP could tag or serve as a proxy for the other SNPs (Fig. 1) . Risk of severe atherosclerosis. In the cross-sectional study, including 5,126 individuals with an ABI Ͼ0.7 and 229 individuals with an ABI Յ0.7, the age-adjusted odds ratio for having an ABI Յ0.7 predicting severe atherosclerosis was 2.01 (95% confidence interval [CI]: 1.34 to 3.01; p ϭ 0.001) for g.Ϫ660 GG versus AA homozygotes ( Fig.  2A, Table 2 ). After adjustment for age, gender, total cholesterol, HDL cholesterol, triglycerides, body mass index, smoking, diabetes mellitus, and hypertension, the equivalent odds ratio was 2.00 (95% CI: 1.33 to 3.02; p ϭ 0.001). Similar results were observed using more extreme cut-off points for ABI (Ͼ0.9 vs. Յ0.7 and Ͼ0.9 vs. Յ0.5) (Figs. 2B and 2C) , as well as for the tag SNPs c.IVS4 -223TϾC and p.A154V (Online Table 2 ). Results were similar assuming a recessive mode of inheritance (Online Table 2 ). The mean ABI values for g.Ϫ660AA, g.Ϫ660AG, and g.Ϫ660GG were 1.02, 1.01, and 1.00, respectively (ANOVA; p ϭ 0.05). Risk of IHD. In the prospective study, the age adjusted hazard ratio for IHD, was 1.21 (95% CI: 1.02 to 1.43; p ϭ 0.03) for g.-660 GG versus AA homozygotes (Fig. 3 , upper left panel; Table 2 ). After adjustment for age, gender, total cholesterol, HDL cholesterol, triglycerides, body mass index, smoking, diabetes mellitus, and hypertension, the equivalent hazard ratio was 1.19 (95% CI: 1.01 to 1.41; p ϭ 0.04).
In the verification samples, case-control studies 1 and 2, the age-adjusted odds ratios for IHD were, respectively, 1.29 (95% CI: 1.02 to 1.62; p ϭ 0.03) and 1.60 (95% CI: 1.34 to 1.92; p ϭ 0.0000003), and the combined odds ratio was 1.48 (95% CI: 1.27 to 1.73; p ϭ 0.0000006) (Fig. 3 , upper middle and right panels; Table 2 ). After adjustment for age and gender, the equivalent odds ratios were, respectively, 1.26 (95% CI: 0.99 to 1.59; p ϭ 0.06), 1.52 (95% CI: 1.26 to 1.83; p ϭ 0.00001), and 1.41 (95% CI: 1.20 to 1.66, p ϭ 0.00002). When IHD was subdivided into MI and angina pectoris, results for g.Ϫ660 GG versus AA were essentially similar for MI in all 3 studies, as well as for angina in the study with the largest number of cases, case-control study 2 (Fig. 3 , middle and lower panels; Online Tables 6 to 9 ). With the exception of the 2 tag SNPs, c.IVS4 -223 and p.A154V, none of the other 6 SNPs were consistently associated with an increased risk of IHD, MI, or angina pectoris (Online Tables 3 to 11) . Results were similar assuming a recessive mode of inheritance (Online Tables 3 to 11 ). Finally, well-known risk 
373
Promoter SNP in ZNF202 and Ischemic Heart Disease factors for atherosclerosis and IHD, including lipids and lipoproteins, did not differ as a function of g.Ϫ660AϾG genotypes (Table 3) . ZNF202 g.؊660A>G promoter function. The relative luciferase activity driven by the ZNF202 promoter with the mutant G at position g.Ϫ660 was consistently reduced by more than 60% compared with the wild-type promoter with A at position g.Ϫ660 (Fig. 4) (p values from 0.01 to 0.004 by Mann-Whitney U test for 3 separate experiments each performed in triplicate and with 2 different DNA preparations). These results indicated that the G allele was associated with reduced transcriptional activity compared with the A allele.
Discussion
The key findings in this study are: 1) ZNF202 g.Ϫ660 GG homozygotes (frequency: 9% in the general population) had an increased risk of severe atherosclerosis, as determined by a low ABI in a cross-sectional study of more than 5,000 individuals from the general population. 2) In a large prospective study of more than 10,000 individuals followed for 28 years with 1,511 incident IHD events, g.Ϫ660 GG homozygosity predicted an increased risk of IHD. The increased risk of IHD associated with GG homozygosity was confirmed in 2 large, independent case-control studies including a total of approximately 2,500 cases with IHD and 9,000 controls.
3) The g.Ϫ660AϾG, G allele, was associated with decreased transcriptional activity in vitro. ZNF202 is located in a susceptibility locus for familial hypoalphalipoproteinemia (5) and is a transcriptional repressor controlling promoter elements predominantly found in genes involved in vascular maintenance and lipid metabolism (7, 9, 10, 22) . For this reason, it is plausible that ZNF202 could be a candidate gene for atherosclerosis and risk of IHD. ZNF202 is known to bind a promoter element found in VEGF, suggesting that a possible mechanism behind our observations could be an effect of genetic variation in ZNF202 on the expression of VEGF. VEGF is a potent angiogenic factor that plays multiple roles in vascular development and maintenance (8) . Several observations indicate that VEGF has proatherosclerotic properties. VEGF enhances atherosclerotic plaque progression (23, 24) and induces plaque destabilization via neovascularization, which increases macrophage accumulation and progression of atherosclerosis (25) . VEGF induces the expression of endothelial adhesion molecules and has chemoattractant properties, suggesting a role for VEGF in leukocyte recruitment (26, 27) . VEGF also stimulates tissue factor expression on endothelial cells and thereby the conversion of prothrombin to thrombin, enhancing a procoagulant state (28) . An altered transcriptional activity of the ZNF202 promoter could result in altered VEGF expression, potentially explaining the observed atherosclerosis and IHD susceptibility.
Other ZNF202 target genes are involved in lipid metabolism (7, 9, 10, 22) . ZNF202 could also influence risk of atherosclerosis and IHD via regulation of 1 or more of these genes. ZNF202 g.Ϫ660AϾG genotype was not associated with variation in plasma levels of total cholesterol, apolipoprotein B, low-density lipoprotein cholesterol, HDL cholesterol, apolipoprotein AI, and triglycerides (Table 3) ; however, this does not preclude an effect on target genes involved in lipid metabolism. In support of this, we have previously shown that a common mutation in the cholesterol transporter ABCA1, a well-known HDL gene and a target gene for ZNF202 (9, 10) , predicts an increased risk of IHD independent of lipid and lipoprotein levels in plasma (29) .
ZNF202 g.Ϫ660AϾG was associated with severe atherosclerosis with IHD and MI in all 3 studies and, in Table 2 ), and an additional 1,213 participants were genotyped for g.Ϫ660AϾG (n ϭ 5,355). ‡p values significant after correction for multiple comparisons using the Bonferroni adjustment method (required corrected p value with 9 SNPs corresponding to 9 comparisons: p ϭ 0.05/9 ϭ 0.006). §A total of 8,942 individuals were genotyped for all 9 SNPs (Online Table 3 ), and an additional 1,489 individuals (n ϭ 10,431) were genotyped for g.Ϫ660AϾG. ʈA total of 942 patients with ischemic heart disease (IHD) and, respectively, 8,998 (g.Ϫ660AϾG) and 7,644 (remaining 8 SNPs) controls were genotyped (Online Table 4 ). ¶A total of 1,549 patients with ischemic heart disease and, respectively, 8,998 (g.Ϫ660AϾG) and 7,644 (remaining 8 SNPs) controls were genotyped (Online Table 5 ).
addition, with angina pectoris in case-control study 2, the study that included by far the largest number of cases with angina (Ͼ900 cases). These results might suggest an effect of g.Ϫ660AϾG on the development of atherosclerotic plaque progression, as well as an effect on plaque stability and thrombosis. As noted above, the target gene VEGF may play a role in the development of all these phenotypes. In a previous study (12) , which included only SNPs in the coding region of ZNF202, a common nonsynonymous SNP, p.A154V, predicted an increased risk of IHD in participants of the CCHS. In the present study, we found that p.A154V was both in tight linkage disequilibrium and highly correlated with g.Ϫ660AϾG and c.IVS4 -223TϾC, raising the question which of these was the functional SNP. Because p.A154V was not conserved between species (human, mouse, rat) and substituted similar amino acids, and because c.IVS4 -223TϾC was not predicted to affect splicing or gene regulation, this suggested that g.Ϫ660AϾG could be the functional SNP. This was confirmed in in vitro expression studies consistently showing decreased transcriptional activity of the g.Ϫ660 G allele.
In the assumption-free model, the g.Ϫ660AϾG genotype was entered as a categorical variable with AA as the reference group, and without an a priori assumption of mode of inheritance. This model was consistently significant only for the comparison of GG versus AA genotype. In agreement with this, and assuming different genetic models a priori (additive, recessive, dominant), a recessive model of inheritance was also the most consistently significant model throughout the studies. Study limitations. Although our studies are very large, and both cross-sectional and prospective and are based on a sample of the general population, there are potential limitations. Misclassification of end points is always a concern; Figure 3 Risk of IHD, MI, and Angina Pectoris as a Function of ZNF202 g.؊660A>G Genotype
Age adjusted hazard ratios (prospective study, left panels) or odds ratios (case-control studies 1 and 2, middle and right panels) with 95% confidence intervals for ischemic heart disease (IHD) (upper panels), for myocardial infarction (MI) (middle panels), and for angina pectoris (lower panels) as a function of ZNF202 g.Ϫ660AϾG genotype in the general population. The AA genotype is the reference group. Prospective study (left panels): n ϭ 1,511 incident cases with IHD, including, respectively, 749 and 762 incident cases with MI or angina pectoris; case-control study 1 (middle panels): n ϭ 942 cases with IHD, including, respectively, 491 and 451 cases with MI or angina pectoris; case-control study 2 (left panels): n ϭ 1,549 cases with IHD, including, respectively, 644 and 905 cases with MI and angina pectoris.
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Promoter SNP in ZNF202 and Ischemic Heart Disease however, MI end points gathered from the national Danish Patient Registry and the national Danish Causes of Death Registry were confirmed independently via medical records of general practitioners and hospitals. Angina pectoris was not confirmed independently, and therefore, some misclassification for angina and thus for the entire IHD group in the prospective study may be present. Despite this, genotypes predicted IHD suggesting that the true association might be stronger than that observed. In support of this possibility, the odds ratios for IHD in the 2 case-control studies were both larger than the hazard ratios for IHD observed in the prospective study: IHD cases in the 2 casecontrol studies were confirmed by stenosis/atherosclerosis on coronary angiography, a previous MI or a positive exercise electrocardiography test. Misclassification of genotypes is very unlikely, because genotype distribution in the general population was in Hardy-Weinberg equilibrium, because genotyping was performed using reliable TaqMan chemistry, and because all data transfer from genotyping equipment to the database was performed electronically, excluding human error in database entry. Another concern in this type of study with multiple comparisons is type I error. One of the currently most widely accepted ways of dealing with type I error is to replicate one's results in different samples. A second way of addressing type I error is to correct for multiple comparisons using 1 of several statistical methods. In this study, we used both approaches. We observed similar results for 3 related end points-severe atherosclerosis, IHD, and MI-in 2 large studies and confirmed these results for IHD and MI in 2 additional, large independent studies, suggesting that these results were not due to type I error. Even after correction for multiple comparisons using the Bonferroni adjustment method, risk of severe atherosclerosis, IHD, MI, and angina pectoris remained significant in 2 studies.
ZNF202 g.-660A>G and Risk Factors for Ischemic Heart Disease Among Individuals From the General Population 
Conclusions
We show that homozygosity for a common functional promoter variant in ZNF202, g.Ϫ660G, predicts severe atherosclerosis and an increased risk of IHD. This suggests that ZNF202 is a candidate gene for atherosclerosis and IHD.
